Optional Activities. The Parties may agree in writing that Company continues with the pre-clinical Development of the Target Compound for a Collaboration Target for which the Stage Gate DPED has been approved, to achieve [***]. In such case, the Parties shall agree on an update of the Research Plan for such Collaboration Target, such that the Research Plan sets forth the [***] criteria and the data package to be provided by Company to Merck for the Research Unit Leadership Teams’ approval on such Target Compound being moved into clinical Development. Sections 3.1, 3.3, 3.4, and 3.5 shall apply mutatis mutandis with respect to such additional activities by Company, and the Research Unit Leadership Teams’ approval on such Target Compound being moved into clinical Development. If Company conducts such [***] activities, submits the agreed data package to Merck, and the Research Unit Leadership Team approves that such Target Compound be moved into clinical Development, Merck shall pay to Company an additional milestone payment of [***], such payment to be made in accordance with Section 7.2.4.
Appears in 2 contracts
Sources: Research Collaboration Agreement (Recursion Pharmaceuticals, Inc.), Research Collaboration Agreement (Exscientia PLC)